An international multicentric phase 1/2 non-comparative study reports the result of PD1 immune checkpoint inhibitor (nivolumab) in 262 patients with advanced HCC and sorafenib untreated/intolerant or sorafenib progressor. 25% of patients have grade 3 or 4 adverse events. The response rate in the escalation phase was 15% with a median overall survival of 15 months. A phase 3 randomized controlled trial comparing nivolumab versus sorafenib is undergoing.

(El-Khoueiry AB et al. – Lancet, 20 April 2017)

Read more